nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—SLC47A1—Mitoxantrone—lymphatic system cancer	0.477	0.586	CbGbCtD
Famotidine—SLC22A2—Cytarabine—lymphatic system cancer	0.214	0.263	CbGbCtD
Famotidine—CYP2C19—Teniposide—lymphatic system cancer	0.0697	0.0856	CbGbCtD
Famotidine—SLC22A8—Methotrexate—lymphatic system cancer	0.0528	0.0648	CbGbCtD
Famotidine—Infection—Fludarabine—lymphatic system cancer	0.000593	0.00319	CcSEcCtD
Famotidine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.000591	0.00318	CcSEcCtD
Famotidine—Decreased appetite—Teniposide—lymphatic system cancer	0.00059	0.00318	CcSEcCtD
Famotidine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000586	0.00315	CcSEcCtD
Famotidine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000585	0.00315	CcSEcCtD
Famotidine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000584	0.00315	CcSEcCtD
Famotidine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000584	0.00315	CcSEcCtD
Famotidine—Rash—Mechlorethamine—lymphatic system cancer	0.000581	0.00313	CcSEcCtD
Famotidine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00058	0.00313	CcSEcCtD
Famotidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00058	0.00313	CcSEcCtD
Famotidine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000575	0.0031	CcSEcCtD
Famotidine—Flushing—Bleomycin—lymphatic system cancer	0.000572	0.00308	CcSEcCtD
Famotidine—Depression—Vincristine—lymphatic system cancer	0.00057	0.00307	CcSEcCtD
Famotidine—Anorexia—Fludarabine—lymphatic system cancer	0.000569	0.00306	CcSEcCtD
Famotidine—Extravasation—Methotrexate—lymphatic system cancer	0.000569	0.00306	CcSEcCtD
Famotidine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00056	0.00301	CcSEcCtD
Famotidine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000555	0.00299	CcSEcCtD
Famotidine—Nausea—Mechlorethamine—lymphatic system cancer	0.000547	0.00295	CcSEcCtD
Famotidine—Alopecia—Bleomycin—lymphatic system cancer	0.000544	0.00293	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000544	0.00293	CcSEcCtD
Famotidine—Jaundice—Mitoxantrone—lymphatic system cancer	0.000543	0.00292	CcSEcCtD
Famotidine—Urticaria—Teniposide—lymphatic system cancer	0.00054	0.00291	CcSEcCtD
Famotidine—Abdominal pain—Teniposide—lymphatic system cancer	0.000537	0.00289	CcSEcCtD
Famotidine—Body temperature increased—Teniposide—lymphatic system cancer	0.000537	0.00289	CcSEcCtD
Famotidine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000536	0.00289	CcSEcCtD
Famotidine—Hallucination—Carmustine—lymphatic system cancer	0.000535	0.00288	CcSEcCtD
Famotidine—Haematuria—Mitoxantrone—lymphatic system cancer	0.000531	0.00286	CcSEcCtD
Famotidine—Dyspepsia—Fludarabine—lymphatic system cancer	0.000525	0.00283	CcSEcCtD
Famotidine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000522	0.00281	CcSEcCtD
Famotidine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00052	0.0028	CcSEcCtD
Famotidine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000519	0.00279	CcSEcCtD
Famotidine—Fatigue—Fludarabine—lymphatic system cancer	0.000515	0.00277	CcSEcCtD
Famotidine—Hallucination—Vincristine—lymphatic system cancer	0.000511	0.00275	CcSEcCtD
Famotidine—Pain—Fludarabine—lymphatic system cancer	0.00051	0.00275	CcSEcCtD
Famotidine—Constipation—Fludarabine—lymphatic system cancer	0.00051	0.00275	CcSEcCtD
Famotidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000509	0.00274	CcSEcCtD
Famotidine—Hypersensitivity—Teniposide—lymphatic system cancer	0.0005	0.00269	CcSEcCtD
Famotidine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.0005	0.00269	CcSEcCtD
Famotidine—Flushing—Carmustine—lymphatic system cancer	0.000499	0.00269	CcSEcCtD
Famotidine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000496	0.00267	CcSEcCtD
Famotidine—Anaemia—Bleomycin—lymphatic system cancer	0.000496	0.00267	CcSEcCtD
Famotidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000492	0.00265	CcSEcCtD
Famotidine—Asthenia—Teniposide—lymphatic system cancer	0.000487	0.00262	CcSEcCtD
Famotidine—Pruritus—Teniposide—lymphatic system cancer	0.000481	0.00259	CcSEcCtD
Famotidine—Arrhythmia—Carmustine—lymphatic system cancer	0.00048	0.00259	CcSEcCtD
Famotidine—Leukopenia—Bleomycin—lymphatic system cancer	0.00048	0.00259	CcSEcCtD
Famotidine—Alopecia—Carmustine—lymphatic system cancer	0.000475	0.00256	CcSEcCtD
Famotidine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000472	0.00254	CcSEcCtD
Famotidine—Mental disorder—Carmustine—lymphatic system cancer	0.000471	0.00254	CcSEcCtD
Famotidine—Cough—Bleomycin—lymphatic system cancer	0.000468	0.00252	CcSEcCtD
Famotidine—Diarrhoea—Teniposide—lymphatic system cancer	0.000465	0.0025	CcSEcCtD
Famotidine—Chest pain—Bleomycin—lymphatic system cancer	0.000457	0.00246	CcSEcCtD
Famotidine—Myalgia—Bleomycin—lymphatic system cancer	0.000457	0.00246	CcSEcCtD
Famotidine—Alopecia—Vincristine—lymphatic system cancer	0.000454	0.00244	CcSEcCtD
Famotidine—Back pain—Carmustine—lymphatic system cancer	0.000453	0.00244	CcSEcCtD
Famotidine—Mental disorder—Vincristine—lymphatic system cancer	0.00045	0.00242	CcSEcCtD
Famotidine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000447	0.00241	CcSEcCtD
Famotidine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000444	0.00239	CcSEcCtD
Famotidine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000442	0.00238	CcSEcCtD
Famotidine—Confusional state—Bleomycin—lymphatic system cancer	0.000441	0.00238	CcSEcCtD
Famotidine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00044	0.00237	CcSEcCtD
Famotidine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000438	0.00236	CcSEcCtD
Famotidine—Oedema—Bleomycin—lymphatic system cancer	0.000438	0.00236	CcSEcCtD
Famotidine—Infection—Bleomycin—lymphatic system cancer	0.000435	0.00234	CcSEcCtD
Famotidine—Anaemia—Carmustine—lymphatic system cancer	0.000433	0.00233	CcSEcCtD
Famotidine—Back pain—Vincristine—lymphatic system cancer	0.000432	0.00233	CcSEcCtD
Famotidine—Vomiting—Teniposide—lymphatic system cancer	0.000432	0.00233	CcSEcCtD
Famotidine—Agitation—Carmustine—lymphatic system cancer	0.00043	0.00232	CcSEcCtD
Famotidine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000429	0.00231	CcSEcCtD
Famotidine—Asthenia—Fludarabine—lymphatic system cancer	0.000428	0.00231	CcSEcCtD
Famotidine—Rash—Teniposide—lymphatic system cancer	0.000428	0.00231	CcSEcCtD
Famotidine—Dermatitis—Teniposide—lymphatic system cancer	0.000428	0.0023	CcSEcCtD
Famotidine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000426	0.0023	CcSEcCtD
Famotidine—Headache—Teniposide—lymphatic system cancer	0.000426	0.00229	CcSEcCtD
Famotidine—Pruritus—Fludarabine—lymphatic system cancer	0.000422	0.00227	CcSEcCtD
Famotidine—Back pain—Mitoxantrone—lymphatic system cancer	0.000421	0.00227	CcSEcCtD
Famotidine—Leukopenia—Carmustine—lymphatic system cancer	0.000419	0.00226	CcSEcCtD
Famotidine—Anorexia—Bleomycin—lymphatic system cancer	0.000417	0.00225	CcSEcCtD
Famotidine—Anaemia—Vincristine—lymphatic system cancer	0.000413	0.00222	CcSEcCtD
Famotidine—Agitation—Vincristine—lymphatic system cancer	0.000411	0.00221	CcSEcCtD
Famotidine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00041	0.00221	CcSEcCtD
Famotidine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000408	0.0022	CcSEcCtD
Famotidine—Convulsion—Carmustine—lymphatic system cancer	0.000406	0.00218	CcSEcCtD
Famotidine—Nausea—Teniposide—lymphatic system cancer	0.000403	0.00217	CcSEcCtD
Famotidine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000402	0.00217	CcSEcCtD
Famotidine—Leukopenia—Vincristine—lymphatic system cancer	0.0004	0.00215	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000399	0.00215	CcSEcCtD
Famotidine—Myalgia—Carmustine—lymphatic system cancer	0.000399	0.00215	CcSEcCtD
Famotidine—Chest pain—Carmustine—lymphatic system cancer	0.000399	0.00215	CcSEcCtD
Famotidine—Anxiety—Carmustine—lymphatic system cancer	0.000397	0.00214	CcSEcCtD
Famotidine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000393	0.00212	CcSEcCtD
Famotidine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00039	0.0021	CcSEcCtD
Famotidine—Convulsion—Vincristine—lymphatic system cancer	0.000387	0.00209	CcSEcCtD
Famotidine—Confusional state—Carmustine—lymphatic system cancer	0.000385	0.00207	CcSEcCtD
Famotidine—Oedema—Carmustine—lymphatic system cancer	0.000382	0.00206	CcSEcCtD
Famotidine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00038	0.00205	CcSEcCtD
Famotidine—Myalgia—Vincristine—lymphatic system cancer	0.00038	0.00205	CcSEcCtD
Famotidine—Cough—Mitoxantrone—lymphatic system cancer	0.00038	0.00205	CcSEcCtD
Famotidine—Infection—Carmustine—lymphatic system cancer	0.00038	0.00204	CcSEcCtD
Famotidine—Vomiting—Fludarabine—lymphatic system cancer	0.00038	0.00204	CcSEcCtD
Famotidine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000377	0.00203	CcSEcCtD
Famotidine—Rash—Fludarabine—lymphatic system cancer	0.000376	0.00203	CcSEcCtD
Famotidine—Dermatitis—Fludarabine—lymphatic system cancer	0.000376	0.00203	CcSEcCtD
Famotidine—Pain—Bleomycin—lymphatic system cancer	0.000374	0.00202	CcSEcCtD
Famotidine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000374	0.00201	CcSEcCtD
Famotidine—Headache—Fludarabine—lymphatic system cancer	0.000374	0.00201	CcSEcCtD
Famotidine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000371	0.002	CcSEcCtD
Famotidine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000371	0.002	CcSEcCtD
Famotidine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000371	0.002	CcSEcCtD
Famotidine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000369	0.00199	CcSEcCtD
Famotidine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000365	0.00196	CcSEcCtD
Famotidine—Oedema—Vincristine—lymphatic system cancer	0.000365	0.00196	CcSEcCtD
Famotidine—Anorexia—Carmustine—lymphatic system cancer	0.000364	0.00196	CcSEcCtD
Famotidine—Infection—Vincristine—lymphatic system cancer	0.000362	0.00195	CcSEcCtD
Famotidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000361	0.00194	CcSEcCtD
Famotidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000358	0.00193	CcSEcCtD
Famotidine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000357	0.00192	CcSEcCtD
Famotidine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000355	0.00191	CcSEcCtD
Famotidine—Oedema—Mitoxantrone—lymphatic system cancer	0.000355	0.00191	CcSEcCtD
Famotidine—Nausea—Fludarabine—lymphatic system cancer	0.000355	0.00191	CcSEcCtD
Famotidine—Infection—Mitoxantrone—lymphatic system cancer	0.000353	0.0019	CcSEcCtD
Famotidine—Shock—Mitoxantrone—lymphatic system cancer	0.000349	0.00188	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000348	0.00187	CcSEcCtD
Famotidine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000348	0.00187	CcSEcCtD
Famotidine—Urticaria—Bleomycin—lymphatic system cancer	0.000348	0.00187	CcSEcCtD
Famotidine—Anorexia—Vincristine—lymphatic system cancer	0.000348	0.00187	CcSEcCtD
Famotidine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000346	0.00186	CcSEcCtD
Famotidine—Insomnia—Carmustine—lymphatic system cancer	0.000346	0.00186	CcSEcCtD
Famotidine—Irritability—Methotrexate—lymphatic system cancer	0.000344	0.00185	CcSEcCtD
Famotidine—Paraesthesia—Carmustine—lymphatic system cancer	0.000343	0.00185	CcSEcCtD
Famotidine—Somnolence—Carmustine—lymphatic system cancer	0.00034	0.00183	CcSEcCtD
Famotidine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000339	0.00182	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000332	0.00179	CcSEcCtD
Famotidine—Decreased appetite—Carmustine—lymphatic system cancer	0.000332	0.00179	CcSEcCtD
Famotidine—Insomnia—Vincristine—lymphatic system cancer	0.00033	0.00178	CcSEcCtD
Famotidine—Paraesthesia—Vincristine—lymphatic system cancer	0.000327	0.00176	CcSEcCtD
Famotidine—Constipation—Carmustine—lymphatic system cancer	0.000327	0.00176	CcSEcCtD
Famotidine—Pain—Carmustine—lymphatic system cancer	0.000327	0.00176	CcSEcCtD
Famotidine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000324	0.00175	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000324	0.00174	CcSEcCtD
Famotidine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000322	0.00174	CcSEcCtD
Famotidine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000319	0.00172	CcSEcCtD
Famotidine—Decreased appetite—Vincristine—lymphatic system cancer	0.000317	0.00171	CcSEcCtD
Famotidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000316	0.0017	CcSEcCtD
Famotidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000315	0.0017	CcSEcCtD
Famotidine—Fatigue—Vincristine—lymphatic system cancer	0.000314	0.00169	CcSEcCtD
Famotidine—Asthenia—Bleomycin—lymphatic system cancer	0.000314	0.00169	CcSEcCtD
Famotidine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000313	0.00168	CcSEcCtD
Famotidine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000312	0.00168	CcSEcCtD
Famotidine—Constipation—Vincristine—lymphatic system cancer	0.000312	0.00168	CcSEcCtD
Famotidine—Pain—Vincristine—lymphatic system cancer	0.000312	0.00168	CcSEcCtD
Famotidine—Pruritus—Bleomycin—lymphatic system cancer	0.00031	0.00167	CcSEcCtD
Famotidine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000309	0.00166	CcSEcCtD
Famotidine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000306	0.00165	CcSEcCtD
Famotidine—Pain—Mitoxantrone—lymphatic system cancer	0.000304	0.00164	CcSEcCtD
Famotidine—Constipation—Mitoxantrone—lymphatic system cancer	0.000304	0.00164	CcSEcCtD
Famotidine—Abdominal pain—Carmustine—lymphatic system cancer	0.000302	0.00163	CcSEcCtD
Famotidine—Body temperature increased—Carmustine—lymphatic system cancer	0.000302	0.00163	CcSEcCtD
Famotidine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000298	0.00161	CcSEcCtD
Famotidine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000298	0.00161	CcSEcCtD
Famotidine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000296	0.00159	CcSEcCtD
Famotidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000293	0.00158	CcSEcCtD
Famotidine—Dysuria—Methotrexate—lymphatic system cancer	0.000291	0.00157	CcSEcCtD
Famotidine—Neutropenia—Methotrexate—lymphatic system cancer	0.000291	0.00157	CcSEcCtD
Famotidine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00029	0.00156	CcSEcCtD
Famotidine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000289	0.00156	CcSEcCtD
Famotidine—Body temperature increased—Vincristine—lymphatic system cancer	0.000288	0.00155	CcSEcCtD
Famotidine—Abdominal pain—Vincristine—lymphatic system cancer	0.000288	0.00155	CcSEcCtD
Famotidine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000287	0.00154	CcSEcCtD
Famotidine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000284	0.00153	CcSEcCtD
Famotidine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000282	0.00152	CcSEcCtD
Famotidine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000281	0.00152	CcSEcCtD
Famotidine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000281	0.00151	CcSEcCtD
Famotidine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000281	0.00151	CcSEcCtD
Famotidine—Vomiting—Bleomycin—lymphatic system cancer	0.000278	0.0015	CcSEcCtD
Famotidine—Depression—Methotrexate—lymphatic system cancer	0.000277	0.00149	CcSEcCtD
Famotidine—Rash—Bleomycin—lymphatic system cancer	0.000276	0.00149	CcSEcCtD
Famotidine—Dermatitis—Bleomycin—lymphatic system cancer	0.000276	0.00148	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000275	0.00148	CcSEcCtD
Famotidine—Asthenia—Carmustine—lymphatic system cancer	0.000274	0.00148	CcSEcCtD
Famotidine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000269	0.00145	CcSEcCtD
Famotidine—Haematuria—Methotrexate—lymphatic system cancer	0.000265	0.00142	CcSEcCtD
Famotidine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000262	0.00141	CcSEcCtD
Famotidine—Asthenia—Vincristine—lymphatic system cancer	0.000262	0.00141	CcSEcCtD
Famotidine—Diarrhoea—Carmustine—lymphatic system cancer	0.000261	0.00141	CcSEcCtD
Famotidine—Nausea—Bleomycin—lymphatic system cancer	0.00026	0.0014	CcSEcCtD
Famotidine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000259	0.00139	CcSEcCtD
Famotidine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000255	0.00137	CcSEcCtD
Famotidine—Dizziness—Carmustine—lymphatic system cancer	0.000253	0.00136	CcSEcCtD
Famotidine—Diarrhoea—Vincristine—lymphatic system cancer	0.00025	0.00134	CcSEcCtD
Famotidine—Hepatitis—Methotrexate—lymphatic system cancer	0.000249	0.00134	CcSEcCtD
Famotidine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000247	0.00133	CcSEcCtD
Famotidine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000243	0.00131	CcSEcCtD
Famotidine—Vomiting—Carmustine—lymphatic system cancer	0.000243	0.00131	CcSEcCtD
Famotidine—Dizziness—Vincristine—lymphatic system cancer	0.000241	0.0013	CcSEcCtD
Famotidine—Rash—Carmustine—lymphatic system cancer	0.000241	0.0013	CcSEcCtD
Famotidine—Dermatitis—Carmustine—lymphatic system cancer	0.000241	0.0013	CcSEcCtD
Famotidine—Headache—Carmustine—lymphatic system cancer	0.000239	0.00129	CcSEcCtD
Famotidine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000236	0.00127	CcSEcCtD
Famotidine—Tinnitus—Methotrexate—lymphatic system cancer	0.000232	0.00125	CcSEcCtD
Famotidine—Vomiting—Vincristine—lymphatic system cancer	0.000232	0.00125	CcSEcCtD
Famotidine—Rash—Vincristine—lymphatic system cancer	0.00023	0.00124	CcSEcCtD
Famotidine—Dermatitis—Vincristine—lymphatic system cancer	0.00023	0.00124	CcSEcCtD
Famotidine—Headache—Vincristine—lymphatic system cancer	0.000228	0.00123	CcSEcCtD
Famotidine—Nausea—Carmustine—lymphatic system cancer	0.000227	0.00122	CcSEcCtD
Famotidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000226	0.00122	CcSEcCtD
Famotidine—Rash—Mitoxantrone—lymphatic system cancer	0.000224	0.00121	CcSEcCtD
Famotidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000224	0.0012	CcSEcCtD
Famotidine—Headache—Mitoxantrone—lymphatic system cancer	0.000223	0.0012	CcSEcCtD
Famotidine—Alopecia—Methotrexate—lymphatic system cancer	0.00022	0.00119	CcSEcCtD
Famotidine—Mental disorder—Methotrexate—lymphatic system cancer	0.000218	0.00118	CcSEcCtD
Famotidine—Nausea—Vincristine—lymphatic system cancer	0.000217	0.00117	CcSEcCtD
Famotidine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000212	0.00114	CcSEcCtD
Famotidine—Nausea—Mitoxantrone—lymphatic system cancer	0.000211	0.00114	CcSEcCtD
Famotidine—Back pain—Methotrexate—lymphatic system cancer	0.00021	0.00113	CcSEcCtD
Famotidine—Anaemia—Methotrexate—lymphatic system cancer	0.0002	0.00108	CcSEcCtD
Famotidine—Leukopenia—Methotrexate—lymphatic system cancer	0.000194	0.00105	CcSEcCtD
Famotidine—Cough—Methotrexate—lymphatic system cancer	0.000189	0.00102	CcSEcCtD
Famotidine—Convulsion—Methotrexate—lymphatic system cancer	0.000188	0.00101	CcSEcCtD
Famotidine—Chest pain—Methotrexate—lymphatic system cancer	0.000185	0.000994	CcSEcCtD
Famotidine—Arthralgia—Methotrexate—lymphatic system cancer	0.000185	0.000994	CcSEcCtD
Famotidine—Myalgia—Methotrexate—lymphatic system cancer	0.000185	0.000994	CcSEcCtD
Famotidine—Confusional state—Methotrexate—lymphatic system cancer	0.000178	0.000961	CcSEcCtD
Famotidine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000177	0.000953	CcSEcCtD
Famotidine—Infection—Methotrexate—lymphatic system cancer	0.000176	0.000947	CcSEcCtD
Famotidine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000173	0.000933	CcSEcCtD
Famotidine—Anorexia—Methotrexate—lymphatic system cancer	0.000169	0.000908	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000161	0.000868	CcSEcCtD
Famotidine—Insomnia—Methotrexate—lymphatic system cancer	0.00016	0.000862	CcSEcCtD
Famotidine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000159	0.000856	CcSEcCtD
Famotidine—Somnolence—Methotrexate—lymphatic system cancer	0.000157	0.000847	CcSEcCtD
Famotidine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000156	0.000839	CcSEcCtD
Famotidine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000154	0.000828	CcSEcCtD
Famotidine—Fatigue—Methotrexate—lymphatic system cancer	0.000153	0.000822	CcSEcCtD
Famotidine—Pain—Methotrexate—lymphatic system cancer	0.000151	0.000815	CcSEcCtD
Famotidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000146	0.000785	CcSEcCtD
Famotidine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000145	0.000779	CcSEcCtD
Famotidine—Urticaria—Methotrexate—lymphatic system cancer	0.000141	0.000757	CcSEcCtD
Famotidine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00014	0.000753	CcSEcCtD
Famotidine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00014	0.000753	CcSEcCtD
Famotidine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00013	0.000702	CcSEcCtD
Famotidine—Asthenia—Methotrexate—lymphatic system cancer	0.000127	0.000684	CcSEcCtD
Famotidine—Pruritus—Methotrexate—lymphatic system cancer	0.000125	0.000674	CcSEcCtD
Famotidine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000121	0.000652	CcSEcCtD
Famotidine—Dizziness—Methotrexate—lymphatic system cancer	0.000117	0.00063	CcSEcCtD
Famotidine—Vomiting—Methotrexate—lymphatic system cancer	0.000113	0.000606	CcSEcCtD
Famotidine—Rash—Methotrexate—lymphatic system cancer	0.000112	0.000601	CcSEcCtD
Famotidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000111	0.0006	CcSEcCtD
Famotidine—Headache—Methotrexate—lymphatic system cancer	0.000111	0.000597	CcSEcCtD
Famotidine—Nausea—Methotrexate—lymphatic system cancer	0.000105	0.000566	CcSEcCtD
